Biosyent Pharma announces that they have commenced the Canadian launch of Cysview®

In a news release November 17th, BioSyent announces that CYSVIEW® has been approved by Health Canada and BioSyent is now commencing the launch.

Bladder cancer is the fourth most common cancer in men in Canada, and each year 8000 patients are diagnosed with bladder cancer. René Goehrum, President and CEO of Biosyent, says Biosyent is proud to bring this innovative technology to Canada to help doctors better detect and manage bladder cancer. To read the news release from BioSyent click here